Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities

Xuan Zhang, Tao Wu, Xinyi Cai, Jianhua Dong, Cuifeng Xia, Yongchun Zhou, Rong Ding, Renfang Yang, Jing Tan, Lijuan Zhang, Ya Zhang, Yuqin Wang, Chao Dong, Yunfeng LiFrontiers in Immunology 2022 · DOI

Abstract: Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit. However, patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT). The 2015 KEYNOTE-016 trial identified MSI-H/dMMR as a biomarker indicative of immunotherapy efficacy, and pointed to the potential use of immune checkpoint inhibitors (ICIs). In 2017, the FDA approved two ICIs (pembrolizumab and nivolumab) for treatment of MSI-H/dMMR metastatic CRC (mCRC). In 2018, the CheckMate-142 trial demonstrated successful treatment of mCRC based on "double immunity" provided by nivolumab with ipilimumab, a regimen that may become a standard first-line treatment for MSI-H mCRC. In 2018, the FDA approved nivolumab alone or with ipilimumab for patients who progressed to MSI-H/dMMR mCRC after standard chemotherapy. The FDA then approved pembrolizumab alone as a first-line treatment for patients with MSI-H/dMMR CRC that was unresectable or metastatic. There is now interest in using these drugs in neoadjuvant immunotherapy (nIT) for patients with MSI-H/dMMR non-mCRC. In 2020, the NICHE trial marked the start of using nIT for CRC. This novel treatment of MSI-H/dMMR LACRC may change the approaches used for neoadjuvant therapy of other cancers. Our review of immunotherapy for CRC covers diagnosis and treatment, clinical prognostic characteristics, the mechanism of nIT, analysis of completed prospective and retrospective studies, and ongoing clinical trials, and the clinical practice of using nIT for MSI-H/dMMR LACRC. Our team also proposes a new organ-preservation strategy for patients with MSI-H/dMMR low LARC.

Introduction: The Challenge of MSI-H/dMMR LACRC

Locally advanced colorectal cancer (LACRC) is typically managed through a multimodal approach involving neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT), followed by surgery. However, approximately 15% of CRC patients possess the microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) molecular subtype. These patients derive significantly less benefit from standard chemotherapy regimens; for instance, the FOxTROT study reported an effective response rate of only 4.7% for this group. Consequently, there is an urgent clinical need for alternative neoadjuvant strategies for these "chemo-resistant" but "immunologically hot" tumors.

Mechanism of Neoadjuvant Immunotherapy

The biological rationale for neoadjuvant immunotherapy (nIT) lies in the high Tumor Mutational Burden (TMB) and neoantigen density characteristic of MSI-H/dMMR tumors. These features make the tumors highly visible to the immune system once immune checkpoints (PD-1/PD-L1 or CTLA-4) are inhibited.

A key concept is the "Training Ground" hypothesis: administering immunotherapy while the primary tumor is intact allows it to serve as a reservoir of neoantigens. This environment "trains" T-cells to recognize and attack tumor cells, creating a systemic immune response that can eliminate occult micro-metastases more effectively than adjuvant therapy administered after the primary tumor has been removed.

Schematic of the mechanism of neoadjuvant immunotherapy in MSI-H/dMMR LACRC, illustrating T-cell activation and tumor cell death.

Clinical Efficacy and Trial Outcomes

Recent clinical trials have demonstrated that nIT can achieve unprecedented rates of tumor regression in MSI-H/dMMR patients. The landmark NICHE trial showed that 100% of dMMR patients achieved a pathological response, with 60% reaching a pathological Complete Response (pCR). Similarly, the VOLTAGE-A study found a 60% pCR rate when nivolumab was administered following standard chemoradiotherapy.

Summary of completed clinical trials evaluating neoadjuvant immunotherapy strategies and their efficacy in colorectal cancer.

These results suggest that nIT is not only highly effective but also safe, as it does not appear to increase surgical complexity or postoperative complications. In many cases, the response is so profound that it opens the door for organ-preservation strategies.

Opportunities for Organ Preservation

For patients with locally advanced rectal cancer (LARC), the achievement of a Clinical Complete Response (cCR) through nIT presents a provocative opportunity: the "Watch & Wait" strategy. By avoiding radical surgery, patients can be spared life-altering complications such as permanent stomas or fecal incontinence. Our team has observed significant regression in 100% of MSI-H/dMMR patients treated with nIT at our center, with several successfully opting for non-operative management.

Future Directions and Limitations

While the results are promising, several hurdles remain before nIT becomes the standard of care. Most current data stems from Phase II trials or retrospective series, necessitating large-scale Phase III validation. Furthermore, while MSI-H status is a strong predictor of response, it is not absolute. Future research must focus on refining biomarkers—such as TMB, Tumor Neoantigen Burden (TNB), and tumor microenvironment (TME) scores—to identify potential non-responders. Long-term follow-up is also essential to ensure that organ-preservation strategies do not compromise overall survival compared to traditional surgical resection.

Summary updated

Abstract

Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit. However, patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT). The 2015 KEYNOTE-016 trial identified MSI-H/dMMR as a biomarker indicative of immunotherapy efficacy, and pointed to the potential use of immune checkpoint inhibitors (ICIs). In 2017, the FDA approved two ICIs (pembrolizumab and nivolumab) for treatment of MSI-H/dMMR metastatic CRC (mCRC). In 2018, the CheckMate-142 trial demonstrated successful treatment of mCRC based on "double immunity" provided by nivolumab with ipilimumab, a regimen that may become a standard first-line treatment for MSI-H mCRC. In 2018, the FDA approved nivolumab alone or with ipilimumab for patients who progressed to MSI-H/dMMR mCRC after standard chemotherapy. The FDA then approved pembrolizumab alone as a first-line treatment for patients with MSI-H/dMMR CRC that was unresectable or metastatic. There is now interest in using these drugs in neoadjuvant immunotherapy (nIT) for patients with MSI-H/dMMR non-mCRC. In 2020, the NICHE trial marked the start of using nIT for CRC. This novel treatment of MSI-H/dMMR LACRC may change the approaches used for neoadjuvant therapy of other cancers. Our review of immunotherapy for CRC covers diagnosis and treatment, clinical prognostic characteristics, the mechanism of nIT, analysis of completed prospective and retrospective studies, and ongoing clinical trials, and the clinical practice of using nIT for MSI-H/dMMR LACRC. Our team also proposes a new organ-preservation strategy for patients with MSI-H/dMMR low LARC.
BibTeX
@inproceedings{zhang2022neoadjuvant,
  author = {Xuan Zhang and Tao Wu and Xinyi Cai and Jianhua Dong and Cuifeng Xia and Yongchun Zhou and Rong Ding and Renfang Yang and Jing Tan and Lijuan Zhang and Ya Zhang and Yuqin Wang and Chao Dong and Yunfeng Li},
  title = {{Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.795972},
}
Figure